Background A giant cell tumor of bone is a primary benign but locally aggressive neoplasm. Malignant transformation in a histologically typical giant cell tumor of bone, without radiotherapy exposure, is an uncommon event, occurring in less than 1% of giant cell tumors of bone. Although surgery is the standard initial treatment, denosumab, a monoclonal antibody drug that inhibits receptor activator of nuclear factor-jB ligand (RANKL), has shown considerable activity regarding disease and control of symptoms in patients with recurrence, unresectable, and metastatic giant cell tumors of bone. Case Description We report the case of a 20-year-old woman with a recurrent benign, giant cell tumor of bone, who had a bone sarcoma develop while receiving denosumab treatment. Literature Review To our knowledge, there have been no reports of infection or malignancy with low-dose denosumab administration for osteoporosis. However, while there are relatively few reported side effects, the safety of denosumab and adverse events seen with higher doses, as used in treatment of giant cell tumors of bone are not well defined. Clinical Relevance Denosumab has become a valuable adjunct for treatment of recurrent or unresectable giant cell tumor of bone. It is not clear if our patient's malignant transformation of a giant cell tumor of bone while receiving denosumab treatment was caused by denosumab, but it is important to be aware of the possibility if more cases occur. Future studies should focus on the safety of highdose denosumab administration in patients with a benign unresectable giant cell tumor of bone.
Introduction
A giant cell tumor of bone is a primary benign but locally aggressive neoplasm [14] . The tumor has characteristic large multinucleated osteoclast-like giant cells expressing receptor activator of nuclear factor-jB (RANK) and mesenchymal spindle-like stromal cells expressing RANK ligand (RANKL); this cell interaction leads to bone resorption [17, 23] . Although surgery is the standard primary treatment, denosumab, a monoclonal antibody drug that inhibits RANKL, has shown considerable activity regarding disease and symptoms in cases of recurrent and metastatic giant cell tumor of bone [4] .
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We describe the case of a patient with a benign recurrent giant cell tumor of bone who had a secondary malignant giant cell tumor of bone develop during treatment with denosumab. Evaluation of the entire specimen from the curettage confirmed the histologic diagnosis giant cell tumor of bone (Fig. 1E, F) .
Case Report
One year after the first procedure, the patient presented at our center with right knee pain. Radiographic and CT studies revealed an osteolytic lesion that destroyed the posterior cortex of the allograft and the tibia ( Fig. 2A, B) . A CT-guided biopsy showed recurrent giant cell tumor of bone; therefore, a proximal tibal en bloc resection was performed in August 2010 ( Fig. 2C, D) . The histologic features of the specimen were consistent with a benign giant cell tumor of bone (Fig. 2E ). The patient's postoperative course was uneventful until January 2013, when a followup radiograph and CT showed a new local soft tissue recurrence in the popliteal fossae ( Fig. 3A ). An intralesional resection was performed in February 2013. The histologic features of the recurrence corresponded to a benign giant cell tumor of bone, just as had the previous specimens ( Fig. 3B ). Owing to the local aggressiveness of the tumor and the belief that a radical resection was not feasible, in May 2013 we decided to initiate treatment with denosumab as an adjuvant to avoid future recurrences. The administration began with a 360 mg subcutaneous dose, then 120 mg subcutaneously monthly (every 28 days) according to current FDA-approved protocol [22] . By October 2013, we observed clearly demarcated osteosclerosis of the recurrent mass located in the popliteal region ( Fig. 4 ). Pain around the patient's right knee diminished but another tumor resection was recommended as it recently was reported that although denosumab almost completely eliminates the expression of RANKL and histologic evaluation shows the absence of giant cells, the neoplastic stromal cells component may persist and regrow [10] .
Because of the patient's clinical improvement, however, she refused surgical resection and continued with denosumab treatment. The clinical improvement persisted until June 2014, when a rapidly growing, painful, palpable mass was detected in the popliteal fossa. A CT scan revealed that the palpable mass involved two different sections with two levels of density: a low-density component and a highdensity, calcified component ( Fig. 5A ). An open biopsy was performed, obtaining samples from both components. When histologically analyzing the specimens, we observed that the low-density component, previously identified with CT scan, corresponded to a high-grade sarcoma ( Fig. 5 B,  C) , while the high-density component corresponded to areas of giant cell tumor of bone with changes related to denosumab treatment ( Fig. 5 D-F) . Denosumab-related changes comprise depletion or absence of giant cells, fibrosis, and ossification. As no associated regional lymphadenopathy was detected, and chest CT showed no evidence of metastases, an above-knee amputation was performed. The amputation specimen revealed that the low-density components corresponded to a tan-yellow mass measuring 15 cm 9 7 cm. Histologic analysis of these components showed a high-grade pleomorphic sarcoma with 15 mitoses per high-power field and extensive necrosis (approximately 40% of the tumor). No neoplastic bone formation was observed. Histologic analysis of the specimen remainder showed absence of giant cells with persistence of mononuclear stromal cells, fibrosis, and ossification as seen after denosumab treatment.
At last followup, 6 months after the amputation, the patient was disease-free.
Discussion
Giant cell tumor of bone is classified as a benign tumor, although recurrence rates range from 0% to 65%, depending on the type of treatment provided and tumor location [8] . Secondary malignant transformation in a previously histologically typical giant cell tumor of bone without any record of previous radiotherapy is exceptionally uncommon (occurring in less than 1% of patients) [24] ; therefore, only a few case reports address this event [6, 7, 11, 13, 16, 19] .
Although extremely unusual, sarcomas arising in a benign giant cell tumor have been reported [15, 24] . They usually contain areas of benign giant cell tumors and a biopsy may not initially reveal the existence of a malignant tumor [1] . Because our patient had multiple surgical resections with complete histologic analysis of the pathologic specimens, it is improbable that the malignant component would have been present initially and misdiagnosed.
Sarcoma arising in a giant cell tumor of bone may follow radiation therapy or occur in postsurgical recurrences. Some patients may have a giant-cell-rich sarcoma or osteosarcoma at initial diagnosis. Although the sarcoma cannot be distinguished on the basis of radiographic and histologic presentations, it is believed that the etiology differs [1] . Sakkers et al. [19] suggested a theory concerning malignant transformation of giant cell tumor of bone treated by curettage and bone grafting; in this context, reparative proliferative changes that occur at the margins of an area of dead bone could serve as the departure point for development of a malignant tumor.
A giant cell tumor of bone is thought to be biphenotypic, involving osteoclast-like giant cells expressing RANK, and mesenchymal spindle-like neoplastic stromal cells expressing RANKL. The interaction between these cells leads to bone resorption [23] . Denosumab, a monoclonal antibody that binds RANKL and directly inhibits osteoclastogenesis, has shown objective changes in the tumor along with clinical responses in patients with an unresectable tumor or large recurrences who have few other treatment options [25] . It recently was reported that denosumab almost completely eliminates the expression of RANKL, and histologic evaluation shows the absence of giant cells but the persistence of neoplastic stromal cells [10] . We believe that patients treated with denosumab should have a surgical resection after denosumab administration whenever possible to avoid regrowth of the tumor. To our knowledge, there have been no reports of significant adverse events, such as malignancy or infections with lower doses of denosumab administration in patients with osteoporosis (60 mg subcutaneously every 6 months) in the 3-or 6-year Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) extension trial [2] . However, the safety of denosumab and adverse events with higher doses (beginning with a 360-mg dose and then 120-mg monthly every 28 days), as used in treating patients with giant cell tumor of bone, has not been well defined. The effectiveness of denosumab regarding disease and symptom control in patients with an unresectable or recurrent giant cell tumor of bone has been seen, without severe adverse effects [22] ; however, Thomas et al. [22] reported, in a Phase 2 study, that the reason for two of their four patients discontinuing the denosumab regimen before completion of planned treatment was because of disease progression of a malignant giant cell tumor of bone. Additionally although five patients had serious adverse events, none were deemed to be treatmentrelated. It has been questioned if RANKL inhibitors affect inflammation and immunity, as RANKL is expressed by endothelial cells, T lymphocytes, synovial fibroblasts, and various tumor cells [5] . Nevertheless, no meaningful clinical extraskeletal effects have been reported after denosumab administration for osteoporosis, and the overall rate of infections, cancer, and patient mortality have been similar with denosumab use compared with placebo at doses used for the treatment of patients with osteoporosis [5, 20] . High-dose denosumab therapy, similar to that used in patients with an unresectable giant cell tumor of bone, was recommended for prevention of skeletal-related events in patients with bone metastasis from a solid tumor [21] . In that study, it was difficult to assess long-term side effects related to denosumab therapy as patients had a limited life expectancy owing to the oncologic disease [21] .
We present the findings of a patient who had a sarcoma develop in a previously benign, recurrent giant cell tumor of bone while receiving denosumab therapy. We cannot confirm whether denosumab treatment was causative or contributed to the development of the sarcoma or whether this was coincidental. We do believe, however, that this finding should be reported because denosumab is being used more frequently in the treatment of patients with a benign giant cell tumor of bone. Treating physicians should be aware of the possible association and further prospective studies should focus on the safety of denosumab therapy when used in high doses for treatment of patients with a benign unresectable giant cell tumor of bone.
